ProMIS Neurosciences (PMN) Net Cash Flow (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Net Cash Flow came in at $57.7 million in Q1 2026, up 1271.09% YoY from $4.2 million in Q1 2025, and up 721.62% on a QoQ basis from -$9.3 million in Q4 2025.
ProMIS Neurosciences (PMN) Net Cash Flow (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Net Cash Flow data on file, last reported at $57.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 1271.09% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (up 488.04% YoY) and the FY2025 annual result came in at -$7.2 million, down 1135.27% from the prior year.
- Net Cash Flow improved to $57.7 million in Q1 2026, from -$9.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $57.7 million in Q1 2026 to a low of -$10.1 million in Q1 2024.
- A 5-year average of $110751.1 and a median of -$4.3 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 294.32% — and 2026, when it surged 1271.09%.
- Tracing PMN's Net Cash Flow over 5 years: stood at -$4.6 million in 2022, then grew by 6.25% to -$4.3 million in 2023, then plunged by 93.14% to -$8.2 million in 2024, then declined by 12.58% to -$9.3 million in 2025, then jumped by 721.62% to $57.7 million in 2026.
- The last three Net Cash Flow figures came in at $57.7 million (Q1 2026), -$9.3 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 225.59 Mn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | -10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.40 Mn |
| Jun 30, 2026 | -10.40 Mn |
| Mar 31, 2026 | 57.70 Mn |
| Mar 31, 2026 | 57.70 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | -8.25 Mn |
| Dec 31, 2024 | -8.25 Mn |
| Sep 30, 2024 | 20.54 Mn |
| Sep 30, 2024 | 20.54 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -10.10 Mn |
| Mar 31, 2024 | -10.10 Mn |